CAMBRIDGE, Mass., May 2, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the Deutsche Bank 37th Annual Health Care Conference in Boston. Marc D. Beer, CEO of Aegerion, is scheduled to present on Monday, May 7, 2012 at 10:40 a.m. ET.
Aegerion will also participate in the Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas. Mr. Beer is scheduled to present on Thursday, May 17, 2012 at 11:40 a.m. ET (8:40 a.m. PT).
The presentations will be webcast live and may be accessed for 90 days following the conference by visiting the "Investors" section of Aegerion's website, www.aegerion.com.
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) is an emerging biopharmaceutical company focused on the development and commercialization of novel, breakthrough therapeutics to treat debilitating and often fatal rare diseases. Aegerion is motivated by its commitment to patients first. We are also attentive to our core values of integrity, innovation, responsibility to healthcare providers, development of employees and always – scientific and clinical excellence.